As always with Q3 reporting, the market’s focus tends to fast-forward to the following year. This year, we like what
we see for 2022. Healthcare company managements are signalling confidence in the post-pandemic outlook. They have learned to live with endemic COVID. Company-specific factors and qualities are re-gaining prominence.
We attended the ASCO 2023 annual meeting in Chicago. After the rise of immuno-oncology, COVID-19 challenged clinical trial execution and muted patient numbers. In the last years we saw many setbacks of once promising immuno-oncology combinations trials.
What mattered this month in healthcare? Q1 reporting came to a close, and FTC action put pressure on the biopharma space and... Find out more in our monthly healthcare newsletter.
With M&A picking up, are we at a turning point for biotech? Check out our latest Kieger AG Chart of the Month Video.